查詢結果分析
相關文獻
- Light Chain Escape Multiple Myeloma Complicated with Catastrophic Extramedullary Plasmacytoma Following Novel Agent Treatment
- 鼻腔髓外漿細胞瘤--病例報告
- Multiple Myeloma Associated with Extramedullary Plasmacytoma Causing Nerve Root Compression:A Case Report
- 口咽後壁髓外漿細胞瘤--病例報告
- High Dose Chemotherapy and Allogenic Peripheral Blood Stem Cell Transplantation for Multiple Myeloma Evolving from Intra-Abdominal Plasmacytoma
- Orbital Manifestation of Multiple Myeloma--A Rare Case Report
- 抗癌新藥Rituximab--以抗CD20單株抗體來治療復發性低惡性度非何杰金氏淋巴瘤
- Docetaxel (Taxotere)--治療乳癌與肺癌的新藥
- 中央健保局新藥核價作業之評論
- Multiple Myeloma Presenting with a Paraspinal Tumor and Malignant Effusion: Case Report
頁籤選單縮合
題 名 | Light Chain Escape Multiple Myeloma Complicated with Catastrophic Extramedullary Plasmacytoma Following Novel Agent Treatment=經多線新藥治療後多發性骨髓瘤產生之“輕鍊脫逃”現象及災難性髓外漿細胞瘤 |
---|---|
作 者 | 洪逸平; 楊靜芬; 蕭樑材; | 書刊名 | 臺灣癌症醫學雜誌 |
卷 期 | 1:1 2014.06[民103.06] |
頁 次 | 頁39-45 |
分類號 | 415.6 |
關鍵詞 | 多發性骨髓瘤; 輕鏈脫逃; 髓外漿細胞瘤; 新藥; 血漿游離輕鏈檢查; Multiple myeloma; Light chain escape; Extramedullary plasmacytoma; Novel agents; Serum free light chain; |
語 文 | 英文(English) |
中文摘要 | 多發性骨髓瘤的治療在近幾年來蓬勃的發展,使得病患的存活時間幾乎延長至兩 倍,不過,存活時間的進步也導致一些原本不常見的臨床情況出現,” 輕鏈脫逃”和”髓外 漿細胞瘤”就是其中的代表。在這裡我們提出了一個多發性骨髓瘤的臨床案例,就是在接受了包含傳統化療、自體幹細胞移植、以及標靶藥物後同時發生了這兩種現象,這個病 患的治療結果是令人失望的。但是我們從這個案例學到了一些經驗:第一、免疫球蛋白 的檢查在多發性骨髓瘤的監控上可能不是一個可靠的工具,需要合併腎功能檢查、骨骼 檢查、以及血漿游離輕鍊檢查,才能得到最好的監測效果;第二,髓外漿細胞瘤仍是一 個非常難治療的病症,仍有賴後續的研究來發展出真正有效的治療藥物,以幫助更多的 病患。 |
英文摘要 | The treatment of multiple myeloma (MM) has made greatly advances over the last decade, nearly doubling the overall survival time after the use of novel agents such as thalidomide, lenalidomide and bortezomib. However, the improvement of overall survival has occasionally led to clinical scenarios that were rarely recognized before, for example, light chain escape and extramedullary plasmacytoma (EMP). Here we report an MM patient who relapsed and manifested simultaneously with both a light chain escape and a disseminated pattern of EMP after several different modes of treatment, including conventional chemotherapy, autologous peripheral blood stem cell (PBSC) transplantation, and novel agents. The result was disappointing in this case, which taught us several important things: First, intact immunoglobulin may not be a reliable marker in the surveillance of pretreated multiple myeloma. Various tests for renal function, skeletal condition, and serum free light chain should also be carried out for a comprehensive evaluation. Second, EMP remains a tremendous challenge to the clinician, especially when refractory to current novel agents. Further researches are required to clarify the optimal treatment of such a condition in order to help more patients. |
本系統中英文摘要資訊取自各篇刊載內容。